This site uses cookies to collect activity data and personalize content. By continuing to navigate this site, you agree to allow us to collect information using cookies. Learn more about how we care for your data in our privacy notice.

Accept

Self-injection best practices: designing family planning programs that work

June 18, 2018 by PATH

A woman self-injects the contraceptive DMPA-SC (brand name Sayana Press)

A woman self-injects the contraceptive DMPA-SC (brand name Sayana Press). Photo: PATH/Gabe Bienczycki

Research in Uganda and elsewhere has shown that women are able to self-administer DMPA-SC safely and effectively, that they like doing so, and that self-injection helps support women to continue using injectable contraception.

As the Uganda Ministry of Health plans for national rollout of this new option for women, PATH’s DMPA-SC Self-injection Best Practices initiative is gathering information about how the practice can be designed and implemented at scale. The team in Uganda has applied user-centered design techniques to develop, implement, and evaluate self-injection program models across delivery channels: public-sector facilities, community-based distribution, private-sector outlets, and safe spaces for young women and adolescent girls. The first program data in mid-2018 showed that at least 3,000 women are self-injecting across four districts.

As PATH evaluates these programs, we are regularly sharing insights and lessons learned. If you are planning a self-injection program in your country please feel free to email FPoptions@path.org. For more information, see the resources listed below, visit www.path.org/dmpa-sc, orsign up for our newsletter.

*DMPA-SC: Subcutaneous depot medroxyprogesterone acetate

Sayana Press is a registered trademark of Pfizer Inc.

“ It saves time to inject at home, and it’s private. Another reason is you get courage. I used to fear the needle so much. ”
— Self-injection client, Uganda

Resources

Read More